US FDA OK's Horizon Pharma's arthritis drug Duexis
This article was originally published in Scrip
Executive Summary
Horizon Pharma gained US approval of Duexis, a fixed-dose combination of ibuprofen 800mg and famotidine 26.6mg indicated for the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. It also is approved as a therapy to decrease the risk of developing upper gastrointestinal ulcers.